Formulary and support resources
Resources to support you with your decision making and implementation of EYLEA® (aflibercept) 8 mg for the treatment of neovascular (wet) age-related macular degeneration (nAMD) in adults and the treatment of visual impairment due to diabetic macular oedema (DMO) in adults.
EYLEA 8 mg represents a line extension from the currently available EYLEA 2 mg dose.
NICE has determined that a new technology appraisal is therefore not required.
As it is a line extension, implementation of EYLEA 8 mg may differ between local health systems. This page contains resources to support your formulary update activities across a range of likely scenarios.
Click below to view guides based on the EYLEA 8 mg Summary of Product Characteristics (SmPC) and further information to support a formulary application.
All of the information you might require regarding pack size, storage, how to use EYLEA 8 mg can be found here.
VALUE-BASED PRESCRIBING: ENHANCING NHS EFFICIENCY AND SUSTAINABILITY IN OPHTHALMOLOGY CARE
Dr Elizabeth Wilkinson
Consultant Medical Ophthalmologist, Clinical Director Transformation, Clinical Director
Centre of Excellence for Eyes - Nightingale, Exeter
Clinical Director Eyecare - NHS England SW Royal Devon University Healthcare NHS Foundation Trust
Dr Luke Nicholson
Director of the Medical Retina Service - Moorfields Eye Hospital NHS Foundation Trust
Instructions for use and handling of EYLEA 8 mg in patients with nAMD and DMO.[1]
Prescribing Information:
UK EYLEA (aflibercept) 2 mg & 8 mg: Prescribing Information (PI)
PP-MACS-GB-0268, June 2024